Imricor Medical Systems

The Business

Imricor makes the NorthStar system, a capital device that lets cardiologists perform catheter ablation (a procedure that scars faulty heart tissue to stop abnormal rhythms) while watching in real time on an MRI scanner rather than an X-ray. This matters because MRI avoids radiation exposure and shows soft tissue that X-ray cannot. Revenue comes from selling the console hardware, then a razor-and-blade model of disposable catheters per procedure. The company has almost no revenue today: US$292,000 in FY25, generated entirely from a handful of European hospitals.

Recent Performance

European revenue fell 70% in FY25 as commercial procedures were cannibalised by clinical trial activity, a decline management frames as strategic but that also reflects five years of slow hospital adoption (roughly one to two new sites annually). The US market opened in July 2026, and two hospitals signed within two weeks, a faster start than Europe ever produced. The stock has re-rated sharply on that launch, well ahead of any revenue to justify it.

Outlook

We expect revenue to climb materially from a small FY26 base as US site installations ramp over the next two years, but the fixed cost base (roughly US$30m annually in R&D, sales and administration) means operating losses persist at a similar scale to today through the forecast period. On our base case, the business does not reach cash breakeven until several years into the US rollout, at a revenue level well above anything achieved in Europe to date. That timing, more than any margin assumption, is what determines whether this investment works.

Key Risks

Regulatory rejection of the adult ablation approval would confine the company to a much smaller paediatric-only market, insufficient to support the current cost base. A repeat of the slow European adoption curve in the US would leave revenue stuck well below the level needed to reach breakeven. Cash runway of roughly 2.5 years against a multi-year path to breakeven implies a meaningful chance of another dilutive capital raise before the business is self-funding.

What to Watch

The thesis-defining event is the pace of new US hospital site announcements through Q4 2026 into 2027, which will confirm whether America adopts faster than Europe did.

• Q4 2026-H1 2027 PMA trial completion and regulatory submission — approval unlocks the adult ablation market, the majority of the company's total addressable opportunity.
• Q1 2027 First disclosed US pricing data — will confirm or challenge per-site revenue assumptions underlying the current forecast.

Company Description

Imricor operates a single integrated business: the design, manufacture and sale of MRI-compatible cardiac ablation equipment. The NorthStar console and workstation form the capital equipment layer, sold once per hospital site. Consumables, principally steerable ablation and mapping catheters, generate the recurring revenue layer per procedure. The company also earns a small service and support contract stream from installed sites. Geographically, the business has operated in Europe under CE marking since the mid-2010s and only began US commercial sales in July 2026 following FDA clearance.

Where the Growth Is

Every dollar of forward growth comes from US hospital site installations. The base is tiny today, under US$1m in trailing revenue, but two sites signed within two weeks of the July 2026 launch, versus roughly one to two sites per year across five years in Europe. Our base case assumes 80-120 sites over ten years, but this is the single most consequential and least proven assumption in the entire model, and the gap between the European track record and the early US signal is wide enough that either outcome remains plausible.

Competitive Position

Imricor is the only company in the world with a commercially cleared MRI-guided cardiac intervention platform. Building a competing product would require years of device development and a regulatory pathway that has already consumed two decades and 92 patents for Imricor. No competitor has announced a rival programme. That advantage looks durable for the next five to seven years on current visibility. The risk to this position is not direct replication but obsolescence: pulsed field ablation (PFA), a newer energy source gaining share in atrial fibrillation treatment, could reduce the clinical case for MRI guidance in that indication. Imricor has demonstrated PFA compatibility within its own MRI platform, which partially neutralises this threat, but the largest single ablation market may still shrink in relevance.

Management & Capital Discipline

Founder and CEO Steve Wedan has led the company for its full 20-year history and has overseen genuinely strong regulatory execution, with 14 of 15 FDA submission modules now complete. That capital, however, has been funded almost entirely through dilutive equity raises: shares outstanding grew 108% over the past 2.5 years. Management's public framing of the European revenue decline as a deliberate trial-prioritisation choice understates how weak actual commercial adoption has been over five years of selling effort.

Financial Position

Imricor holds roughly US$70m in cash and short-term securities with no interest-bearing debt, providing approximately 2.5 years of runway at the current burn rate of roughly US$28m annually. Cumulative cash required to reach our modelled breakeven point is closer to US$124m, meaning the existing balance sheet does not fund the company through to profitability. A further capital raise before breakeven looks more likely than not.